| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
-Fetoprotein and Its Application in Early Detection of Hepatocellular Carcinoma in Patients with Hepatic Disease
1 Laboratori d’Analisis Clíniques,
2
Secció de Gastroenterologia, and
3
Servei d’Anatomia Patologica, Hospital Sant Joan de Déu, Althaia Xarxa Assistencial de Manresa, Dr. Joan Soler, s/n 08243 Manresa, Barcelona, Spain
4 Laboratoris Clínics Hospital Vall d’Hebron, 08035. Barcelona, Spain
aauthor for correspondence: fax 34-93-8743859, e-mail hgmlaboratorio{at}aehh.org
Hepatocellular carcinoma (HCC) is one of the most frequent types of cancer worldwide, with an incidence of 150 cases per 100 000 inhabitants per year in Asia and Africa and 
5 cases per 100 000 per year in Europe, North America, and Australia (1). HCC can occur in healthy livers, but it is generally associated with hepatic disease. Cirrhosis is the most important risk factor for its development (2).
Many studies have been dedicated to the early detection of HCC in patients with chronic liver disease (CLD), based on semiannual or annual measurement of serum 
-fetoprotein (AFP) and ultrasound study of the liver. The interpretation of AFP results usually involves comparison with a fixed cutoff ranging from 20 to 500 µg/L, with sensitivities ranging from 33% to 64% (3)(4)(5). Another approach would be to assess changes in consecutive results from the same patient.
To establish a criterion for dynamic assessment of a specific biological constituent, the first step is to define when a difference between two consecutive results indicates a change in a patient’s health status. The most widely accepted approach for this purpose is the so-called reference change value (RCV), a concept described by Harris and Brown (6). Using serial analytic results from the same individual for a specific constituent, it is possible to calculate the RCV that defines how large a difference between two consecutive determinations is statistically significant (P <0.05). The RCV encompasses both biological and analytical variation.
The RCV has been determined for various constituents in healthy persons and in some pathologies (7)(8)(9)(10)(11)(12)(13). In diseases that can modify the homeostatic set point and the degree of fluctuation of a specific constituent, the within-subject biological variation (BV) may be different from that of persons who do not have these diseases (13)(14)(15). This is seen in AFP determinations for the early detection of HCC in patients with CLD. These patients present with higher AFP values than healthy individuals and with abnormal patterns of AFP release because of processes of hepatic necrosis/regeneration (16)(17).
The index of individuality (I.I.) of an analyte indicates whether significant changes in a patient’s health status can be detected by comparing the analytic results with a population-based cutoff value or whether each patient should be evaluated against him- or herself (18).
The aims of this study were as follows: (a) to estimate the BV of AFP in patients with hepatic disease and in patients with nonhepatic conditions, comparing the two groups; (b) to establish analytic quality goals for AFP determinations; and (c) to calculate the RCV of AFP and evaluate its application in the early detection of HCC in a separate group of CLD patients.
Two subgroups, a non-hepatic and a hepatic disease group, were studied to determine the components of analytical variation and BV for AFP. The RCV value obtained was then validated by applying it to a third group consisting of patients with CLD who were included in a program for early detection of HCC.
Thirty patients (15 men and 15 women) with colon adenocarcinoma (Astler–Coller classification stages A or B1) treated surgically were studied to determine the BV components for AFP. For 3 years after the procedure, three samples from each patient were assayed every 6 months. During the study period, there was no evidence of recurrence.
BV values for AFP were also determined in 85 clinically stable patients, 40 with chronic hepatitis and no clinical evidence of cirrhosis and 45 with evidence of cirrhosis, classified according to the Child–Pugh Index (CPI) as A (18 cases), B (15 cases), or C (12 cases).
The RCV value obtained for AFP was applied to 124 CLD patients [67 men and 57 women; mean (SD) age, 60.4 (13.7) years] from July 1997 to June 2001. The CLD etiologies included 67 with hepatitis C viral infections, 48 with alcoholism, and 9 with miscellaneous conditions; 49 patients had chronic active hepatitis and no clinical evidence of cirrhosis, and 75 had clinical evidence of cirrhosis (CPI A, n = 35; CPI B, n = 26; CPI C, n = 14). The clinical criteria to define cirrhosis included CLD and one or more of the following signs: ascites, encephalopathy, upper digestive tract bleeding attributable to esophageal varices, portal hypertension as determined by ultrasound or endoscopy, bilirubin >25 µmol/L, albumin <36 g/L, and prothrombin time (international normalized ratio) >1.3.
The sensitivity and specificity of the RCV were compared with two cutoff values for AFP (20 µg/L, for high sensitivity; and 200 µg/L, for high specificity) that are widely reported in the literature (5)(19)
The mean monitoring period was 20 months (range, 12–48 months), with AFP measurements and abdominal ultrasound studies every 6 months. The mean number of determinations per patient was 4.4 (range, 3–10). When the difference between two consecutive AFP results was higher than the RCV criteria but ultrasound findings were normal, abdominal computed tomography (CT) was performed.
HCC was diagnosed by ultrasound- or CT-guided fine-needle puncture aspiration of the lesion and histologic study. In addition, one patient suspicious by ultrasound, CT scan, and AFP >200 µg/L was entered in the liver transplant program. HCC was diagnosed by observation of the lesion in the extracted organ.
Serum AFP concentrations were measured by electrochemiluminescent analysis on an ELECSYS 2010 instrument (Roche Diagnostics). Samples from the non-hepatic group were tested in a single analytical run. Samples from the hepatic disease group were determined on the same day of collection.
Statistical analyses were performed with the Kolmogorov–Smirnov and Mann–Whitney U-tests. Within-run imprecision, as the CV, was 2.5% (n = 10) for a mean AFP value of 4.1 µg/L (obtained with replicates of a patient sample). Between-run imprecision was 7.1% (n = 720) for a mean AFP value of 8.1 µg/L obtained with Precinorm (Roche Diagnostics).
The variations of AFP values around the mean in the two study groups (non-hepatic and hepatic disease) did not follow a gaussian distribution; thus, logarithmic transformation was applied (9).
The within-subject BV (CVw) was calculated from the experimental variation, using the following formula:
 |
The between-subject BV (CVg) was calculated with the following formula:
 |
The I.I. was calculated according to the following formula:
 |
 |
are the numbers of samples, the median AFP concentrations, and the analytical, within-subject, and between-subject CVs, as well as the I.I. and RCV values for the groups studied.
|
Fifteen of the 124 patients in the validation group were diagnosed with HCC. In four patients, the first sign of HCC was a significant increase in AFP concentrations as determined by the RCV, giving a sensitivity of 26.7% as the first sign. A simultaneous increase in AFP and ultrasound features indicative of HCC were present in 5 of the 15 HCC cases detected; 1 patient had values of 5–18 µg/L (<20 µg/L), with a significant RCV. Six of 15 presented with ultrasound findings as the first sign; 5 of these did not show an increase in AFP over the RCV (or >20 µg/L), and 1 presented with an increase (from 24 to 40 µg/L) that was below the RCV. Among the four cases in which an increase in AFP was the first sign of HCC, abdominal CT disclosed tumors smaller than 3 cm in three patients; in the fourth patient, the tumor was seen on the following ultrasound control at 6 months.
The sensitivity and specificity of the RCV for detecting HCC compared with those of the corresponding fixed cutoff values in the validation group are shown in Fig. 1A
. The diagnostic efficacy was also calculated, based only on the subset of patients with AFP values >20 µg/L (Fig. 1B
).
|
AFP measurements and ultrasound examination of the liver have been used to detect small, asymptomatic tumors in cirrhotic patients, allowing application of effective therapy with increased survival rates (20)(21). The laboratory can provide early evidence of changes in the health status of these patients if it is able to maintain its between-run imprecision below one-half the within-subject BV (22)(23)(24)(25) for AFP.
The incidence of HCC in CLD obtained in this study was 3.02%, similar rates reported for the northern Mediterranean geographic area (3)(21).
These additional findings are worthy of mention:
In conclusion, the RCV is a useful tool for dynamic monitoring of AFP in patients with hepatic disease, demonstrating good sensitivity and specificity that increase when applied to patients with high AFP values.
References
-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 Western patients. Hepatogastroenterology 2000;47:1654-1658.[Medline]
[Order article via Infotrieve]
-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis. Hepatogastroenterology 1993;40:347-351.[Medline]
[Order article via Infotrieve]
-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002;36:410-417.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. K. Aarsand, P. H. Petersen, and S. Sandberg Estimation and Application of Biological Variation of Urinary {delta}-Aminolevulinic Acid and Porphobilinogen in Healthy Individuals and in Patients with Acute Intermittent Porphyria. Clin. Chem., April 1, 2006; 52(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Comin-Anduix, A. Gualberto, J. A. Glaspy, E. Seja, M. Ontiveros, D. L. Reardon, R. Renteria, B. Englahner, J. S. Economou, J. Gomez-Navarro, et al. Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays Clin. Cancer Res., January 1, 2006; 12(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Trape, J. Perez de Olaguer, J. Buxo, and L. Lopez Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer Clin. Chem., January 1, 2005; 51(1): 219 - 222. [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) and sensitivity (
) of the RCV and cutoff to predict HCC in all patients in the program for early detection of HCC (A) and in patients with AFP >20 µg/L (B).